What SK Pharma does

SK-Pharma (legal entity: K.S. Kim International (SK-Pharma) Ltd) is a privately held, family-owned pharmaceutical company headquartered in Tel Aviv, Israel, founded in 2006. The company manufactures, distributes, and markets generic, specialty pharma, hybrid generics, complex generics, and biosimilar pharmaceutical products across more than 18 countries, with therapeutic area concentration in oncology, immunology, ophthalmology, cardiovascular, diabetes, CNS/neurology, and rare/orphan diseases. SK-Pharma operates through a group structure of five wholly-owned subsidiaries: KS-Kim (Israeli market registration and distribution), DrugsIntel (AI/ML-powered data intelligence platform branded 'The Compass'), Orphan Drug Division (rare disease market access), Alzimind (early dementia and Alzheimer's precision medicine), and Obesio (machine learning-based personalized weight management). The company reports more than 300 cumulative product launches with the majority described as first-to-market value-added medicines.

The business model is B2B pharmaceutical distribution: SK-Pharma sells through direct sales relationships with hospitals, clinics, and healthcare providers, supplemented by regional distribution partners across the Balkans, CIS region, Malta, and other markets. Revenue is generated primarily through one-time product sales of specialty and complex generic pharmaceuticals, with a recurring element from the Orphan Drug Division's global market access and distribution activities. Distribution channels include the company's Belgrade regional headquarters (opened 2017) for Balkan operations and additional offices in Malta and Belarus. Pricing is quote-based B2B and not publicly disclosed.

Underlying technology centers on the proprietary DrugsIntel platform, which aggregates unique pharmaceutical data sets and applies AI and ML models for product selection, launch strategy, and supply chain optimization. The company holds multiple regulatory certifications including GMP (5-year valid since 2018 from the Israeli Ministry of Health), ISO 9001:2015, GDP, ISO 27001, and ISO 27799. SK-Pharma has built strategic alliances with more than 300 partner companies and is recognized as one of Israel's fastest-growing healthcare companies (ranked #1 in healthcare in 2022 Israeli Business Rankings).

Name

SK Pharma

Legal name

K.S. Kim International (SK-Pharma) Ltd

Website

https://sk-pharma.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

SK-Pharma is an Israeli-headquartered pharmaceutical company that develops, manufactures, and distributes generic, specialty, complex generic, and orphan drugs across 18+ countries, operating through subsidiaries spanning AI-driven market intelligence, rare disease access, and precision medicine.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals
• Specialty medicines
• Orphan drugs
• Complex generics
• Pharmaceutical distribution

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: SK-Pharma generates revenue through the manufacture, sale, and marketing of generic, specialty pharma, hybrid generics, and biosimilar pharmaceutical products across oncology, immunology, and orphan diseases.
2. Market Access and Distribution: Revenue from global market access and distribution of orphan drugs and rare disease medications through the dedicated Orphan Drug Division.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

SK-Pharma Group manufactures, sells, and markets generic, specialty pharma, hybrid generics, and biosimilar pharmaceutical products across oncology, immunology, antibiotics, cardiovascular, CNS/neurology, ophthalmology, diabetes, and respiratory therapeutic areas in 18+ countries. The group operates five divisions: KS-Kim (Israeli distribution), DrugsIntel (AI/ML BI platform 'The Compass'), Orphan Drug Division (rare diseases), Alzimind (early dementia detection), and Obesio (ML-based weight management). The portfolio includes over 100 products spanning value-added medicines, complex generics, and biosimilars.

Product overview

SK-Pharma is a global pharmaceutical company operating as a group of subsidiaries with a portfolio of over 100 pharmaceutical products. The group structure includes: KS-Kim (Israeli market registration and distribution), DrugsIntel (AI/ML-powered data intelligence platform called 'The Compass'), Orphan Drug Division (rare disease medications), Alzimind (early dementia detection), and Obesio (ML-based weight management). The core product portfolio spans multiple therapeutic categories including oncology (bortezomib, lenalidomide, dasatinib, arsenic trioxide), antibiotics (daptomycin, meropenem, ertapenem), cardiovascular (dabigatran, rivaroxaban, ticagrelor), diabetes (sitagliptin, vildagliptin, vildamed), respiratory (flusalmer), CNS/neurology (duloxetine, fampridine, amfexon, metadex), ophthalmology (brinzolamide, brinzotol), and hepatology (entecavir, emfovir). The company also offers value-added medicines, precision medicines, and complex generics alongside its subsidiary brands.

Differentiator

Problem solved

Functional benefit

Products and services

• Esoprim S.K. 40mg PPI inhibitor (proton pump inhibitor) for reducing stomach acid production, sold to healthcare providers and pharmacies.
• Esoprim Control PPI inhibitor OTC formulation for acid-related conditions, the company's first over-the-counter consumer healthcare product.
• Bortezomib S.K. 3.5mg Oncology medication for the treatment of multiple myeloma, supplied to hospitals and oncology specialists.
• Lenalidomide S.K. (5mg, 10mg, 15mg, 20mg, 25mg) Oncology medication for multiple myeloma and myelodysplastic syndromes, supplied to hospital oncology pharmacies.
• Dasatinib S.K. (20mg, 50mg, 70mg, 100mg, 140mg) Oncology medication for the treatment of chronic myeloid leukemia.
• Rivaroxaban S.K. (2.5mg, 10mg, 15mg, 20mg) Anticoagulant medication for the prevention of blood clots and stroke, supplied to hospitals and pharmacies.
• Dabigatran S.K. 150mg Anticoagulant/thrombolytic medication for the prevention of blood clots.
• Sitagliptin S.K. (25mg, 50mg, 100mg) DPP-4 inhibitor medication for the management of type 2 diabetes.
• Duloxetine S.K. 60mg Antidepressant medication for the treatment of depression and anxiety disorders.
• Brinzolamide S.K. Ophthalmic glaucoma agent for reducing intraocular pressure, supplied to ophthalmology clinics and pharmacies.
• Entecavir S.K. 0.5mg Antiviral medication for the treatment of Hepatitis B.
• Emfovir S.K. 200/245mg HIV/antiviral combination medication for the treatment of HIV.
• Daptomycin S.K. 500mg Antibiotic medication for serious gram-positive bacterial infections, supplied to hospitals.
• Ertapenem S.K. Antibiotic from the carbapenem class for the treatment of serious bacterial infections.
• Meropenem / Anfarm 500mg Broad-spectrum antibiotic for the treatment of serious infections, supplied to hospitals.
• FAMPRIDINE S.K. 10 MG Multiple sclerosis medication for improving walking ability in patients with walking disability (EDSS 4-7).
• ICATIBANT S.K. Bradykinin B2 receptor antagonist for the symptomatic treatment of acute hereditary angioedema (HAE) attacks, an orphan drug indication.
• LMX4 Topical anesthetic for the skin prior to venous cannulation, venipuncture, and painful topical procedures.
• METHEREX S.K. Urinary tract infection medication for prophylaxis and treatment of UTIs, supplied to pharmacies and hospitals.
• Ryaltris Antihistamine nasal spray for the treatment of allergic rhinitis, containing Mometasone Furoate and Olopatadine.
• Amfexon 10mg ADHD medication for the treatment of Attention Deficit Hyperactivity Disorder and Narcolepsy.
• Abiraterone S.K. 250mg Oncology medication for the treatment of prostate cancer.
• Erlotinib S.K. (25mg, 100mg, 150mg) Oncology medication for the treatment of non-small cell lung cancer and pancreatic cancer.
• METADEX XR (10mg, 15mg, 20mg, 30mg) Extended-release ADHD medication for the treatment of attention deficit hyperactivity disorder.
• Lisdexa Oral Solution ADHD medication as an oral solution formulation for pediatric and adult patients.
• KS-Kim (Israeli Market Distribution Division) Wholly-owned subsidiary handling pharmaceutical product registration, marketing strategy, and distribution channel management in the Israeli market.
• DrugsIntel - The Compass AI/ML Data Intelligence Platform DrugsIntel, a wholly-owned SK-Pharma subsidiary, developed The Compass - an exclusive AI/ML technological platform that aggregates unique pharmaceutical data sets, applies data manipulation, unification, and deployment to business intelligence to support intelligent decision-making in product selection, launch strategies, and supply chain optimization.
• Orphan Drug Division Wholly-owned SK-Pharma division excelling in global market access and distribution of orphan drugs for rare diseases, improving patient access to expensive rare disease medications and reducing long patient odysseys.
• Alzimind - Precision Medicine / Early Dementia Detection Wholly-owned SK-Pharma subsidiary operating as a Health Center of Excellence (HCOE) focused on precision medicine for early detection of dementia (EDD) and Alzheimer's Disease, implementing evidence-based methods to enhance early detection.
• Obesio - ML-based Personalized Weight Management Wholly-owned SK-Pharma subsidiary harnessing machine learning techniques to provide a personalized approach to weight loss and obesity management for individual patients.
• Value-Added Medicines Portfolio Enhanced pharmaceutical products that provide additional clinical benefits compared to standard generics, representing the majority of SK-Pharma's first-to-market launches across therapeutic areas.
• Complex Generics Portfolio Technically complex generic medications that are difficult to manufacture, addressing high-cost originator treatments and supplied to healthcare providers across multiple markets.
• Precision Medicines Portfolio Targeted therapies tailored to individual patient characteristics for improved treatment outcomes across oncology, immunology, and rare diseases.

Quantifiable outcome

• 300+ products launched worldwide with majority being first-to-market
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Partnerships

Six partnerships are on record, tiered core and minor.

• Robotics and Artificial Intelligence LLPcoreStrategic or Co-development Partner · 9 February 2026NU graduate-led company that collaborated with Nazarbayev University researchers to develop the A.GEAR Rehabilitation Exoskeleton. Plans to produce at least 5 units this year at Nazarbayev University Technopark, with supply agreement being negotiated with SK-Pharmacy.
• Nazarbayev UniversitycoreStrategic or Co-development Partner · 9 February 2026University researchers developed A.GEAR Rehabilitation Exoskeleton in collaboration with Robotics and AI LLP. The device received state regulatory approval and is moving to mass production.
• ElpenminorStrategic or Co-development PartnerPharmaceutical partner listed in SK-Pharma's Our Partners section, suggesting collaboration in the biopharmaceutical industry.
• RafarmminorStrategic or Co-development PartnerPharmaceutical partner featured in SK-Pharma's partner ecosystem.
• ANFARMminorStrategic or Co-development PartnerPartner company for pharmaceutical products including Meropenem/Anfarm brand.
• Intas B2BminorStrategic or Co-development PartnerB2B pharmaceutical partner in SK-Pharma's distribution network.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Hikma Pharmaceuticals: Jordan-headquartered specialty and generic pharma company with strong MENA, CIS, and Balkans distribution and a branded generics + injectable portfolio that closely mirrors SK-Pharma's specialty/generics mix across emerging markets.
• Dexcel Pharma: Israel-headquartered specialty generics company with a value-added medicines focus and international distribution similar to SK-Pharma, including CNS, cardiology, and specialty therapeutic areas.
• Aurobindo Pharma: India-based global generics manufacturer with deep complex generics, oncology, and biosimilars portfolios that overlap directly with SK-Pharma's catalog and represent the primary pricing-pressure benchmark.
• Dr. Reddy's Laboratories: India-headquartered specialty and generics pharma with active CIS, Balkans, and emerging-markets distribution plus biosimilars — closely aligned with SK-Pharma's geographic and therapeutic footprint.

Broad incumbents

• Teva Pharmaceutical Industries: Israel-based global generics and specialty pharma leader; directly comparable geographic base and broad specialty/generics catalog, though at vastly greater scale, and a direct competitor for Israeli hospital tenders.
• Taro Pharmaceutical Industries: Israel-based generics manufacturer with global reach and a similar complex generics + specialty positioning; competes for Israeli institutional customers and has comparable regulatory expertise.
• Viatris: Global generics and specialty pharma (post Mylan-Upjohn merger) with a broad off-patent portfolio overlapping SK-Pharma's cardiology, oncology, and CNS molecules; benchmark for global generics pricing dynamics.
• Sandoz (Novartis): Global generics and biosimilars leader spun out of Novartis; competes directly with SK-Pharma in complex generics and biosimilars across European and emerging markets.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based pharma group with MENA-focused generics and specialty portfolio; comparable regional distribution model and overlapping therapy areas relevant for SK-Pharma's MENA expansion thesis.
• Tabuk Pharmaceuticals: Saudi-headquartered pharma manufacturer with MENA-focused generics and specialty products; competes for the same regional institutional customers SK-Pharma targets in the Gulf and Levant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/skpharmacompany
• LinkedInlinkedin.com/company/sk--pharma
• Instagraminstagram.com/skpharma_company?igsh=ZTkyMGQyZmdidHNw&utm_source=qr

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SK Pharma